COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity

COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity

IntroductionChronic myeloid leukemia (CML) is a severe hematological malignancy characterized by BCR-ABL fusion gene. The advent of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has improved the landscape of CML treatment dramatically. The occurrence of coronavirus disease 2019 (COVID-19) has...

Full description

Saved in:
Bibliographic Details
Main Authors: Na He, Guosheng Li, Jinting Liu, Wancheng Liu, Ruifeng Tian, Daoxin Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Immunology
Subjects:
Chronic myeloid leukemia
COVID-19
BCR-ABL P210
T cell immunity
TKIs
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1452035/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items